Updated:
Novartis
Novartis formed in 1996 from the merger of Ciba-Geigy and Sandoz, two Swiss chemical and pharmaceutical firms with histories stretching back to the 18th and...
Novartis
Novartis formed in 1996 from the merger of Ciba-Geigy and Sandoz, two Swiss chemical and pharmaceutical firms with histories stretching back to the 18th and 19th centuries. The Sandoz Family Foundation remains a major shareholder and ties the company to one of Europe's enduring industrial fortunes, though Novartis itself is a publicly traded corporate investor, not a family office. Its footprint extends across manufacturing and R&D sites in the United States and a headquarters campus in Basel that houses one of the world's largest corporate art collections. The company operates three divisions — Innovative Medicines, Sandoz, and Alcon — with Innovative Medicines contributing roughly two-thirds of group revenue. Novartis runs an in-house discovery engine built on five technology platforms: chemistry, biotherapeutics, xRNA, radioligand therapy, and gene and cell therapy. Confirmed positions include the strategic RNAi partnership with Argo Biopharma, valued at over $5 billion, and a collaboration with Flagship Pioneering's ProFound Therapeutics. Deployment is global, with marketed medicines registered in more than 150 countries and a stated focus on cardiovascular, renal, metabolic, immunology, neuroscience, and oncology indications. Novartis is expanding its US manufacturing and R&D footprint, with facilities in East Hanover and Morristown, New Jersey, complementing the Basel headquarters. The firm also maintains the Novartis Foundation and Novartis US Foundation for philanthropic activities. In May 2026, the company presented new radioligand therapy data at ASCO and EHA that reinforced its leadership in prostate cancer, breast cancer, and hematology, while separate results at ERA 2026 advanced its position in kidney disease. Novartis differs from typical publicly traded pharma companies in the degree to which it uses its balance sheet like a permanent capital vehicle. It absorbs entire modality platforms — radioligand therapy, xRNA — into its own operations rather than spinning them into separate venture funds. The Sandoz Family Foundation's presence on the shareholder register adds a generational time horizon buffering management from the quarterly earnings pressure that defines most drug makers, even as the firm reports standard financial results.
General information
Firm type
Corporate Investor
Year founded
1996
AUM
Undisclosed
Location
Region
Europe
Country
Switzerland
City
Basel
Corporate office
Basel, Switzerland
Additional offices
East Hanover, NJ, USA · Morristown, NJ, USA
Sector focus
Frequently asked questions
How does Novartis structure its major R&D partnerships?
The firm uses direct strategic alliances rather than traditional venture-fund commitments. The partnership with Argo Biopharma, valued at over $5 billion, is a risk-sharing RNAi collaboration where Novartis co-develops candidates and retains commercialization rights. A separate agreement with Flagship Pioneering's ProFound Therapeutics follows a similar model, giving Novartis access to novel protein targets derived from the dark proteome.
What role does the Sandoz Family Foundation play at Novartis?
The Sandoz Family Foundation is a major shareholder, holding a stake that traces back to the 1996 merger of Ciba-Geigy and Sandoz. While Novartis operates as an independent, publicly traded company, the foundation's presence on the shareholder register provides a long-term capital anchor. The foundation itself is a separate entity with its own philanthropic and investment activities outside the pharmaceutical business.
Which therapeutic areas does Novartis avoid?
Novartis has publicly narrowed its focus to four core areas — cardiovascular, renal and metabolic; immunology; neuroscience; and oncology — and explicitly organizes around five technology platforms rather than broad-spectrum discovery. It does not actively invest in consumer health or animal health, having divested those units in recent years to concentrate capital on high-value specialty medicines.
How does Novartis approach manufacturing and distribution?
The company owns its manufacturing infrastructure, including an expanding US network with facilities in East Hanover and Morristown, New Jersey. Unlike asset-light biotech models, Novartis builds radioligand therapy production sites and gene-therapy manufacturing capacity in-house, aiming to control the supply chain from active pharmaceutical ingredient through to patient delivery in oncology and rare disease indications.
Is Novartis a pharmaceutical company that operates like an investment vehicle?
Novartis is a publicly traded corporate investor that uses its operating cash flow — roughly two-thirds from the Innovative Medicines division — to fund an internal R&D organization resembling a concentrated biotech portfolio. It acquires or partners with platform companies (Argo, ProFound) while absorbing their technology into its own pipeline rather than holding passive fund stakes.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on investors?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: